Blaber Sachiko I, Yoon Hyesook, Scarisbrick Isobel A, Juliano Maria Aparecida, Blaber Michael
Department of Biomedical Sciences, Florida State University, Tallahassee, Florida 32306, USA.
Biochemistry. 2007 May 1;46(17):5209-17. doi: 10.1021/bi6025006. Epub 2007 Apr 7.
Human kallikrein-related peptidase 6 (KLK6) is a member of the kallikrein family of serine-type proteases, characterized as an arginine-specific digestive-type protease capable of degrading a wide-variety of extracellular matrix proteins. KLK6 has been proposed to be a useful biomarker for breast and ovarian cancer prognosis, is abundantly expressed in the CNS and cerebrospinal fluid, and is intimately associated with regions of active inflammatory demyelination in multiple sclerosis (MS) lesions. Inhibition of KLK6 results in delayed onset and reduced severity of symptoms associated with experimental autoimmune encephalomyelitis, suggesting a key effector role for this protease in CNS inflammatory disease. KLK6 has been shown to autolytically cleave internally, leading to inactivation and suggesting a negative feedback inhibition control mechanism. Alternatively, the ability of KLK6 to self-activate has also been reported, suggesting a positive feedback activation loop control mechanism. Activation of pro-KLK6 requires hydrolysis after a Lys residue; however, KLK6 exhibits 2 order of magnitude reduced affinity for hydrolysis after Lys versus Arg residues; therefore, the ability to autolytically activate has been called into question. In the present study the catalytic activity of KLK6 toward its pro-sequence and internal autolytic sequence is characterized. The results show that the ability of KLK6 to activate pro-KLK6 is essentially negligible when compared to the rate of the internal autolytic inactivation or to the ability of other proteases to activate pro-KLK6. The results thus show that the primary autolytic regulatory mechanism of KLK6 is negative feedback inhibition, and activation is likely achieved through the action of a separate protease.
人激肽释放酶相关肽酶6(KLK6)是丝氨酸型蛋白酶激肽释放酶家族的成员,其特征是一种精氨酸特异性消化型蛋白酶,能够降解多种细胞外基质蛋白。KLK6已被认为是乳腺癌和卵巢癌预后的有用生物标志物,在中枢神经系统和脑脊液中大量表达,并且与多发性硬化症(MS)病变中活跃的炎性脱髓鞘区域密切相关。抑制KLK6会导致实验性自身免疫性脑脊髓炎相关症状的发作延迟和严重程度降低,表明该蛋白酶在中枢神经系统炎性疾病中起关键效应作用。已证明KLK6会进行内部自裂解,导致失活,并提示存在负反馈抑制控制机制。另外,也有报道称KLK6具有自我激活的能力,提示存在正反馈激活环控制机制。前体KLK6的激活需要在赖氨酸残基后进行水解;然而,与赖氨酸残基相比,KLK6对赖氨酸残基后水解的亲和力降低了2个数量级;因此,其自我激活的能力受到质疑。在本研究中,对KLK6对其前体序列和内部自裂解序列的催化活性进行了表征。结果表明,与内部自裂解失活速率或其他蛋白酶激活前体KLK6的能力相比,KLK6激活前体KLK6的能力基本可以忽略不计。因此,结果表明KLK6的主要自裂解调节机制是负反馈抑制,激活可能是通过单独一种蛋白酶的作用来实现的。